US Patent Issued to Janssen Biotech, Yuhan on April 14 for "Therapies with 3rd generation EGFR tyrosine kinase inhibitors" (South Korean Inventors)

ALEXANDRIA, Va., April 15 -- United States Patent no. 12,599,606, issued on April 14, was assigned to Janssen Biotech Inc. (Horsham, Pa.) and Yuhan Corp. (Seoul, South Korea).

"Therapies with 3rd generation EGFR tyrosine kinase inhibitors" was invented by Seonmi Kang (Seoul, South Korea) and Sewoong Oh (Suwon-si, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to therapies with 3rd generation EGFR tyrosine kinase inhibitors. Embodiments of the invention relate to the administration of lazertinib to patients diagnosed with non-small cell lung cancer (NSCLC)."

The patent was filed on Aug. 22, 2023, under Application No. 18/453,743.

*For further information, including ...